Tessa Therapeutics Revenue

Biotechnology Research • Bukit Merah, Central Region, Singapore • 21-50 Employees

Tessa Therapeutics revenue & valuation

Annual revenue	$6,700,000
Revenue per employee	$177,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$21,500,000
Total funding	$74,200

Key Contact at Tessa Therapeutics

Ivan Horak

President, RND

Company overview

Headquarters	Depot Road, 138 Depot Road, #07-01, Singapore, Central Singapore 109683, SG
Phone number	+6563840755
Websites	tessacell.com tessatherapeutics.com
NAICS	541714
SIC	873
Employees	21-50
Socials

Tessa Therapeutics Email Formats

Tessa Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	45.6%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	22.3%
{first name}@company.com	john@company.com	15.1%
{first name}{last name}@company.com	johndoe@company.com	9.8%
{first name}_{last name}@company.com	john_doe@company.com	7.2%

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s autologous CD30-CAR-T therapy TT11, is currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. This platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Tessa Therapeutics has 20 employees across 6 departments.

Departments

Number of employees

Funding Data

Explore Tessa Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-07-07	9	$74,200

Funding Insights

$74,200

Total funding amount

$74,200

Most recent funding amount

Number of funding rounds

Tessa Therapeutics Tech Stack

Discover the technologies and tools that power Tessa Therapeutics's digital infrastructure, from frameworks to analytics platforms.

GoDaddy

Hosting

Nginx

Reverse proxies

Sucuri

CDN

DocuSign

Miscellaneous

Microsoft 365

Frequently asked questions

Tessa Therapeutics is located in Bukit Merah, Central Region, SG.

You can reach Tessa Therapeutics at +6563840755.

Tessa Therapeutics generates an estimated annual revenue of $6,700,000. This revenue figure reflects the company's market position and business performance in its industry.

Tessa Therapeutics has an estimated valuation of $21,500,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Tessa Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Tessa Therapeutics has raised a total of $74,200 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Tessa Therapeutics

Ivan Horak

President, RND

4.8

40,000 users